Posted By: Krystle G. Correll
Thu Dec 17th, 2020
As stated in the recently published paper by the IWG (Vargas HM et al, 2020) “The time has come to meaningfully merge nonclinical and clinical data to enable a more comprehensive, but flexible, clinical risk assessment strategy for QTc monitoring”.
Posted By: Krystle G. Correll
Fri Oct 17th, 2014
CiPA (Comprehensive In Vitro Pro-Arrhythmia Assay) is a scientific CSRC/HESI/FDA/SPS-sponsored proposal that aims to define a novel integrated preclinical in vitro/in silico paradigm in which the proarrhythmic potential of new drugs would be primarily assessed using nonclinical in vitro human models
